Kinloch-de Loes S
Department of HIV/Thoracic Medicine, The Royal Free Centre for HIV Medicine, Royal Free Campus, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK.
J Antimicrob Chemother. 2004 Apr;53(4):562-6. doi: 10.1093/jac/dkh132. Epub 2004 Feb 25.
The recent success of highly active antiretroviral therapy (HAART) has altered the prognosis of patients living with HIV-1 infection. However, there are still many challenges to be addressed if we want to develop long-term therapeutic strategies for patients, in both the Western world and resource-poor countries. In this review, the potential role for HIV-1 therapeutic vaccines in the era of HAART will be discussed in the light of the present efforts at developing immune-based therapies to complement antiviral treatment and minimize the duration of exposure to antiviral drugs.
高效抗逆转录病毒疗法（HAART）近期取得的成功改变了HIV-1感染者的预后。然而，无论在西方世界还是资源匮乏国家，若要为患者制定长期治疗策略，仍有许多挑战有待解决。在这篇综述中，鉴于目前在开发基于免疫的疗法以补充抗病毒治疗并尽量缩短抗病毒药物暴露时间方面所做的努力，将讨论HIV-1治疗性疫苗在HAART时代的潜在作用。
